Advisor Group Inc. lifted its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 648.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,755 shares of the biotechnology company’s stock after buying an additional 2,387 shares during the quarter. Advisor Group Inc.’s holdings in bluebird bio were worth $378,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the stock. QS Investors LLC raised its holdings in bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the last quarter. World Asset Management Inc bought a new stake in bluebird bio during the 3rd quarter worth about $230,000. Bank of Montreal Can raised its holdings in bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares during the last quarter. Turner Investments LLC bought a new stake in bluebird bio during the 2nd quarter worth about $184,000. Finally, SG Americas Securities LLC raised its holdings in bluebird bio by 17.9% during the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 295 shares during the last quarter.
Shares of bluebird bio, Inc. (BLUE) opened at $167.80 on Monday. bluebird bio, Inc. has a 52 week low of $60.19 and a 52 week high of $170.20.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The company had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same period last year, the company earned ($2.07) earnings per share. The business’s revenue was up 397.4% compared to the same quarter last year. analysts expect that bluebird bio, Inc. will post -6.68 EPS for the current fiscal year.
In related news, CEO Nick Leschly sold 10,823 shares of the business’s stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $145.05, for a total value of $1,569,876.15. Following the completion of the transaction, the chief executive officer now directly owns 262,409 shares in the company, valued at approximately $38,062,425.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Lynch sold 500 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total value of $60,000.00. Following the completion of the transaction, the director now owns 3,300 shares of the company’s stock, valued at $396,000. The disclosure for this sale can be found here. Insiders sold a total of 191,918 shares of company stock valued at $25,424,178 over the last quarter. 3.90% of the stock is owned by insiders.
Several analysts have weighed in on the company. BidaskClub raised bluebird bio from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. BMO Capital Markets reissued a “buy” rating and set a $108.00 price objective on shares of bluebird bio in a report on Friday, August 4th. Evercore ISI assumed coverage on bluebird bio in a report on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price objective for the company. Wells Fargo & Company reissued an “outperform” rating and set a $158.00 price objective (up from $134.00) on shares of bluebird bio in a report on Tuesday, September 5th. Finally, Maxim Group reissued a “buy” rating and set a $170.00 price objective (up from $100.00) on shares of bluebird bio in a report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $131.05.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.